Absolutely.
When scientists at Tubulis GmbH first asked us this question, we saw it as an exciting opportunity to put our platform to the test in a new application area. Today, we’re proud to share the results of that collaboration in a new white paper demonstrating how Enantios technology can be applied to the measurement and characterization of ADCs.
This is just the beginning. Our study shows the potential in applying innovative, “unconventional” technologies to address the unique challenges of emerging therapeutic classes like ADCs. We are excited to continue pushing these boundaries.
A huge thank you to the Tubulis GmbH team for their trust, collaboration, and support in making this study possible!
Curious to learn more? Email us to receive the white paper or connect with us to explore a POC study: Contact@enantios.com
#antibody-drug conjugates #ADCs #Enantiomers #Chirality #Spectroscopy #Startup
?){kind=link}